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SUMMARY 
 
THE EFFECTS OF ATORVASTATIN ON HEMATOLOGICAL AND 
INFLAMMATORY PARAMETERS 
 
Chronic inflammation may play role in the development of atherosclerosis and 
its complications. In hypercholesterolemia, the evidences of chronic inflammation 
such as the stimulation of chemokines and cytokines, increase in endothelial 
adhesion molecules, and the immune reactions against oxidants on lipoproteins are 
detected. It was shown that statins had some beneficial effects on lipid parameters, 
thrombosis, endothelial dysfunction, smooth muscle proliferation and athersclerosis. 
 In this prospective study, the effects of atorvastatin on hematological and 
inflammatory parameters were investigated on hyperlipidemic patients. 
 Forty patients (14 male and 26 female) with primary hypercholesterolemia, 
according to Adult Treatment Panel for Third Report of National Cholesterol 
Education Program, included to our study. National and local ethical committees 
approved this study. The exclusion criteria were secondary hypercholesterolemia, 
acute coronary syndromes, liver and renal dysfunctions, diabetes mellitus, 
acute/chronic infection and inflammatory diseases, pregnancy, lactation, malignancy, 
and tendency to bleeding. Patients were treated with 20 mg/day atorvastatin for 12 
weeks. At baseline, and 12th weeks, lipid parameters, hematological parameters 
such as whole blood cell counts, hemoglobin and fibrinogen levels, CD3, CD4, CD5, 
CD8, CD14, CD16, CD19, CD40, CD45 using flow-cytometry, inflammatory 
parameters such as interleukin-1 (IL-1), IL-6, IL-18, tumor necrosis factor-alpha 
(TNF-α), interferon-gamma, soluble CD-40, intracellular adhesion molecule-1  
(ICAM-1), vascular cell adhesion molecule-1, high-sensitive CRP, sedimentation rate, 
and enzymes including CK, AST, ALT were evaluated. The results were compared 
with two-paired student’s-t test. Important adverse events were not seen in the 
patients at the end of the study. 
 At the end of study, atorvastatin decreased TC (p<0.001), LDL-C (p<0.001), 
TGs (p=0.006), VLDL-C (p=0.012), and HDL-C (p<0.001). While absolute lymphocyte 
(p=0.003) and platelet counts (p=0.001) were decreased with atorvastatin treatment, 
absolute monocyte count increased (p=0.002).Fibrinogen, high-sensitive CRP, 
sedimentation rate, AST levels were not influenced by atorvastatin theraphy. ALT 
increased at the end of treatment (p=0.041). On flow-cytometric examination, the 
expressions of CD14 (p=0.015) and CD19 (p=0.039) on lymphocytes were 
decreased with atorvastatin. Moreover, atorvastatin decreased the levels of TNF-α 
(p<0.001), sCD40 (p<0.001), ICAM-1 (p<0.001), and IL-18 (p=0.024). IL-1, IL-6, 
VCAM-1 and IFN-γ levels did not changed at the and of the study.  
In conclusion, the anti-platelet and anti-inflammatory effects of atorvastatin, 
independent from lipid-lowering effects, may play an important role on the prevention 
of atherosclerosis, in addition to its beneficial effects on lipid parameters. 
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